nach oben

Der Nervenarzt

Erschienen in:

26.03.2019 | Apoplex | CME

Atypische intrazerebrale Blutungen – Ätiologie und Akutmanagement

verfasst von: J. C. Purrucker, MSc, Prof. Dr. med. T. Steiner, MME

Erschienen in: Der Nervenarzt | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Akutmanagement und Aufarbeitung der Ursachen intrazerebraler Blutungen stellen Kliniker weiterhin vor Herausforderungen. Allein aufgrund der Lokalisation der Blutung („typisch vs. atypisch“) sollte nicht auf die Genese geschlossen werden, da auch „atypisch“ gelegene Blutungen durch eine langjährige arterielle Hypertonie verursacht werden können, wie auch „typisch“ gelegene Blutungen Folge einer „nichthypertensiven“ Ursache sein können. Neben der Diskussion der Einteilung fokussiert dieser Beitrag auf eine Darstellung eines diagnostischen Algorithmus sowie möglicher (seltener) Ursachen für nichttraumatische intrazerebrale Blutungen. Ebenso wird das Management von Blutungen mit besonderem Schwerpunkt auf aktuelle Daten zum Blutdruckmanagement und zum Vorgehen bei Blutungen unter oraler Antikoagulation dargestellt.

Epple C, Brainin M, Steiner T (2014) Intracerebral hemorrhage. In: Brainin M, Heiss W‑D (Hrsg) Textbook of stroke medicine. Cambridge University Press, Cambridge, S 188–205CrossRef

Knudsen KA, Rosand J, Karluk D et al (2001) Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Baillieres Clin Neurol 56:537–539

Linn J, Halpin A, Demaerel P et al (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Baillieres Clin Neurol 74:1346–1350

Rodrigues MA, Samarasekera N, Lerpiniere C et al (2018) The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol 17:232–240CrossRef

Purrucker JC, Hund E, Ringleb PA et al (2013) Cerebral amyloid angiopathy—an underdiagnosed entity in younger adults with lobar intracerebral hemorrhage? Amyloid 20:45–47CrossRef

Charidimou A, Linn J, Vernooij MW et al (2015) Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain 138:2126–2139CrossRef

Charidimou A, Peeters A, Fox Z et al (2012) Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke 43:2324–2330CrossRef

Lovelock CE, Redgrave JN, Briley D et al (2010) The SCAN rule: a clinical rule to reduce CT misdiagnosis of intracerebral haemorrhage in minor stroke. J Neurol Neurosurg Psychiatry 81:271–275CrossRef

Kidwell CS, Wintermark M (2008) Imaging of intracranial haemorrhage. Lancet Neurol 7:256–267CrossRef

10.

Tranvinh E, Heit JJ, Hacein-Bey L et al (2017) Contemporary imaging of cerebral arteriovenous malformations. AJR Am J Roentgenol 208:1320–1330CrossRef

11.

Alexander MD, Yuan C, Rutman A et al (2016) High-resolution intracranial vessel wall imaging: imaging beyond the lumen. J Neurol Neurosurg Psychiatry 87:589–597CrossRef

12.

Vollherbst DF, Bendszus M, Mohlenbruch MA (2018) Intracranial vascular malformations. Nervenarzt 89:1179–1194CrossRef

13.

Rizos T, Jenetzky E, Herweh C et al (2010) Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol 67:788–793PubMed

14.

Ebner M, Birschmann I, Peter A et al (2017) Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care 21:32CrossRef

15.

Ebner M, Birschmann I, Peter A et al (2018) Limitations of specific coagulation tests for direct oral anticoagulants: a critical analysis. J Am Heart Assoc 7:e9807CrossRef

16.

Purrucker JC, Rizos T, Haas K et al (2017) Coagulation testing in Intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants. Neurocrit Care 27:208–213CrossRef

17.

Gosselin RC, Adcock DM, Bates SM et al (2018) International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 118:437–450CrossRef

18.

Drouet L, Bal Dit Sollier C, Steiner T et al (2016) Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used? Int J Stroke 11:748–758CrossRef

19.

Pollack CV Jr., Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran reversal. N Engl J Med 373:511–520CrossRef

20.

Pollack CV Jr., Reilly PA, Van Ryn J et al (2017) Idarucizumab for Dabigatran reversal—full cohort analysis. N Engl J Med 377:431–441CrossRef

21.

Connolly SJ, Milling TJ Jr., Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375:1131–1141CrossRef

22.

Diedler J, Sykora M, Herweh C et al (2011) Intensive care management [corrected] of patients with intracerebral hemorrhage. Nervenarzt 82:431–446CrossRef

23.

Anderson CS, Heeley E, Huang Y et al (2013) Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368:2355–2365CrossRef

24.

Qureshi AI, Palesch YY, Barsan WG et al (2016) Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 375:1033–1043CrossRef

25.

Morotti A, Brouwers HB, Romero JM et al (2017) Intensive blood pressure reduction and spot sign in Intracerebral hemorrhage: a secondary analysis of a randomized clinical trial. Jama Neurol 74:950–960CrossRef

26.

Shoamanesh A, Morotti A, Romero JM et al (2018) Cerebral Microbleeds and the effect of intensive blood pressure reduction on hematoma expansion and functional outcomes: a secondary analysis of the ATACH-2 randomized clinical trial. Jama Neurol 75:850–859CrossRef

27.

Kuramatsu JB, Gerner ST, Schellinger PD et al (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313:824–836CrossRef

28.

Hemphill JC 3rd, Greenberg SM, Anderson CS et al (2015) Guidelines for the management of spontaneous Intracerebral hemorrhage: a guideline for Healthcare professionals from the American heart association/American stroke association. Stroke 46:2032–2060CrossRef

29.

Steiner T, Al-Shahi Salman R, Beer R et al (2014) European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 9:840–855CrossRef

30.

De Havenon A, Majersik JJ, Stoddard G et al (2018) Increased blood pressure variability contributes to worse outcome after Intracerebral hemorrhage: an analysis of ATACH‑2. Stroke 49:1981–1984CrossRef

31.

Baharoglu MI, Cordonnier C, Al-Shahi Salman R et al (2016) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387:2605–2613CrossRef

32.

Frontera JA, Lewin JJ 3rd, Rabinstein AA et al (2016) Guideline for reversal of Antithrombotics in Intracranial hemorrhage: a statement for Healthcare professionals from the Neurocritical care society and society of critical care medicine. Neurocrit Care 24:6–46CrossRef

33.

Naidech AM, Maas MB, Levasseur-Franklin KE et al (2014) Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke 45:2451–2453CrossRef

34.

Estcourt LJ, Stanworth SJ, Collett D et al (2014) Intracranial haemorrhage in thrombocytopenic haematology patients—a nested case-control study: the InCiTe study protocol. BMJ Open 4:e4199CrossRef

35.

Knobl P (2018) Thrombotic thrombocytopenic purpura. Memo 11:220–226CrossRef

36.

Goel R, Ness PM, Takemoto CM et al (2015) Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 125:1470–1476CrossRef

37.

Steiner T, Poli S, Griebe M et al (2016) Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 15:566–573CrossRef

38.

Laible M, Jenetzky E, Beynon C et al (2016) Adverse events following international normalized ratio reversal in Intracerebral hemorrhage. Cerebrovasc Dis 42:446–454CrossRef

39.

Kuramatsu JB, Sembill JA, Gerner ST et al (2018) Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J 39:1709–1723CrossRef

40.

Purrucker JC, Haas K, Rizos T et al (2016) Early clinical and radiological course, management, and outcome of Intracerebral hemorrhage related to new oral anticoagulants. Jama Neurol 73:169–177CrossRef

41.

Wilson D, Seiffge DJ, Traenka C et al (2017) Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Baillieres Clin Neurol 88:1693–1700

42.

Tsivgoulis G, Wilson D, Katsanos AH et al (2018) Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. Ann Neurol 84:694–704CrossRef

43.

Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579CrossRef

44.

Barco S, Cheung WY, Coppens M et al (2016) In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Br J Haematol 172:255–261CrossRef

45.

Brown KS, Wickremasingha P, Parasrampuria DA et al (2015) The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Thromb Res 136:825–831CrossRef

46.

Zahir H, Brown KS, Vandell AG et al (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82–90CrossRef

47.

Cheung YW, Barco S, Hutten BA et al (2015) In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 13:1799–1805CrossRef

48.

Levi M, Moore KT, Castillejos CF et al (2014) Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 12:1428–1436CrossRef

49.

Gerner ST, Kuramatsu JB, Sembill JA et al (2018) Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 83:186–196CrossRef

50.

Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424CrossRef

51.

Sprigg N, Flaherty K, Appleton JP et al (2018) Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 391:2107–2115CrossRef

52.

Langhorne P, Fearon P, Ronning OM et al (2013) Stroke unit care benefits patients with intracerebral hemorrhage: systematic review and meta-analysis. Stroke 44:3044–3049CrossRef

53.

Hanley DF, Lane K, Mcbee N et al (2017) Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 389:603–611CrossRef

54.

Sembill JA, Huttner HB, Kuramatsu JB (2018) Impact of recent studies for the treatment of Intracerebral hemorrhage. Curr Neurol Neurosci Rep 18:71CrossRef

55.

Mendelow AD, Gregson BA, Rowan EN et al (2013) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 382:397–408CrossRef

56.

Hanley DF, Thompson RE, Rosenblum M et al (2019) Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. pii: S0140-6736(19)30195-3. (Epub ahead of print)

57.

Greer DM, Funk SE, Reaven NL et al (2008) Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke 39:3029–3035CrossRef

58.

De Ridder IR, Den Hertog HM, Van Gemert HM et al (2017) PAIS 2 (Paracetamol [acetaminophen] in stroke 2): results of a randomized, double-blind placebo-controlled clinical trial. Stroke 48:977–982CrossRef

59.

Trabert J, Steiner T (2014) Deep vein thrombosis and lung embolisms in patients with stroke: prevention and therapy. Nervenarzt 85:1315–1325CrossRef

60.

Collaboration CT, Dennis M, Sandercock P et al (2013) Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 382:516–524CrossRef

61.

Becker KJ, Baxter AB, Cohen WA et al (2001) Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies. Baillieres Clin Neurol 56:766–772

62.

Veltkamp R, Purrucker J (2017) Management of spontaneous intracerebral hemorrhage. Curr Neurol Neurosci Rep 17:80CrossRef

63.

Nielsen PB, Larsen TB, Skjoth F et al (2015) Restarting anticoagulant treatment after Intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 132:517–525CrossRef

64.

Khanal N, Dahal S, Upadhyay S et al (2015) Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol 6:97–102CrossRef

Titel: Atypische intrazerebrale Blutungen – Ätiologie und Akutmanagement
verfasst von: J. C. Purrucker, MSc
Prof. Dr. med. T. Steiner, MME
Publikationsdatum: 26.03.2019
Verlag: Springer Medizin
Schlagwörter: Apoplex
Hirnblutung
Erschienen in: Der Nervenarzt / Ausgabe 4/2019
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-019-0695-5

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Ein diagnostisches Chamäleon

Leitlinie: Zerebrale Venen- und Sinusthrombose

Die Erstbeschreibung der Schilder-Krankheit

Erklärung zu finanziellen und nichtfinanziellen Interessen in CME-Fortbildungen von Springer Medizin

Therapieevaluation bei Patienten mit 5q-assoziierter spinaler Muskelatrophie

Integrierte Neurorehabilitation verbessert Versorgungseffizienz